Abstract 4093: COSMIC Actionability: Supporting precision oncology through Identification of actionable mutations from clinical trials databases and publications

Abstract

Abstract The availability of drugs that are effective in cancer patients with specific somatic mutations is rapidly evolving. Finding the most recent information is not straightforward; clinical progress and drug approvals are recorded in clinical trial repositories, files from drug regulatory agencies, publications and conference abstracts. Often there is a delay between trials reaching their outcomes, publication and deposition of results in clinical trial databases. COSMIC Actionability is a new addition to COSMIC’s (Catalogue Of Somatic Mutations In Cancer) portfolio of navigational databases for precision oncology. It indicates the availability of drugs that target mutations and tracks the progress of novel drugs through clinical development. All stages of drug development are represented, through safety and clinical efficacy to market approval, with additional data from case studies expanding mutation coverage. For each mutation-cancer type combination, a simple tiered system indicates whether marketed drugs are available and if not, indicates the progress of drug development efforts. Trial records available in databases such as Clinical Trials.gov and EudraCT are supplemented with trials identified in publications. Trial progression and outcomes are recorded; details are sourced from clinical trial databases, publications, conference abstracts, corporate announcements and regulatory authorities such as the FDA. Curation identifies results for approximately 40% more trials than are available in clinical trial databases alone. Like other COSMIC resources, Actionability is manually curated by Ph.D. level experts. The current version of COSMIC Actionability (October 2021) has 49 fully curated genes with a further 237 having some clinical information. Details of 6244 drug-cancer type combinations are available, of which 2224 have clinical results. 963 drugs are represented, in 2224 treatment combinations. 149 point mutations and 520 further mutations or fusions are represented. This dataset will be made freely available in 2022 then released quarterly, with extended gene coverage and updates of previous content. Citation Format: Steven C. Jupe, Nidhi Bindal, Zbyslaw Sondka, Shicai Wang, Sumodh Nair, Laura Ponting, Doron Sondheimer, Charlie Hathaway, Simon A. Forbes. COSMIC Actionability: Supporting precision oncology through Identification of actionable mutations from clinical trials databases and publications [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4093.